Impax's Flomax ANDA Triggers Patent Suit

Law360, New York (July 22, 2008, 12:00 AM EDT) -- Impax Laboratories Inc.'s bid to enter the billion-dollar U.S. market for prostate drug Flomax has prompted Astellas Pharma Inc. and Boehringer Ingleheim Pharmaceuticals Inc. to file a suit accusing Impax of infringing a single patent.

The lawsuit was filed Friday in the U.S. District Court for the Northern District of California.

The suit was triggered by Impax's submission of an abbreviated new drug application for tamsulosin hydrochloride capsules, or generic Flomax.

Impax said its ANDA included a Paragraph IV certification saying its proposed generic does not...
To view the full article, register now.